<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21407908</article-id><article-id pub-id-type="pmc">2957003</article-id><article-id pub-id-type="publisher-id">IJPsy-42-52</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>COMPARATIVE STUDY OF RISPERIDONE AND HALOPERIDOL ON CLINICAL AND PSYCHOSOCIAL PARAMETERS IN TREATMENT OF SCHIZOPHRENIA : A RANDOMISED OPEN TRIAL</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shrivastava</surname><given-names>Amresh</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Gopa</surname><given-names>Sarkhel</given-names></name><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><label>*</label>AMRESH SHRIVASTAVA, MD(Psy)., DPM., Consultant Psychiatrist, Silver Mind Hospital. 209. Shivkripa Complex, Gokhale Road. Thane. Mumbai-400 602.</aff><aff id="aff2">SARKHEL GOPA, MA., (Clinical Psychologist), Consultant Clinical Psychologist, Silver Mind Hospital. 209. Shivkripa Complex, Gokhale Road. Thane. Mumbai-400 602.</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence</bold></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2000</year></pub-date><volume>42</volume><issue>1</issue><fpage>52</fpage><lpage>56</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2000</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The study compares the efficacy of risperidone and haloperidol in patients of schizophrenia on various clinical and psychosocial parameters.</p><p>In the present open, comparative study, in patients suffering from schizophrenia (DSM-IV), 50 patients each were randomly treated with risperidone and haloperidol over a period of 1 year. The clinical improvement was judged on PANSS (Positive and Negative Symptom Scale) and CGIS (Clinical Global Impression Scale). The improvement in psychosocial functioning and other areas was judged using a five point scale (0-4). Though the improvement on PANSS was comparable in both the groups except on the general psychopathology subscale, on CGIS a better improvement profile was observed in risperidone group. In the other psychosocial areas such as social functioning, productivity and education a significantly more number of patients showed improvement in risperidone group as compared to haloperidol group. In significantly less number of patients suicidality and rehospitalization was found in risperidone group as compared to haloperidol group.</p></abstract><kwd-group><kwd>Risperidone</kwd><kwd>haloperidol</kwd><kwd>social integration</kwd><kwd>quality of life</kwd></kwd-group></article-meta></front></article>